MRD tracking in blood using a de novo sequencing from SPEP gel of M-protein in Multiple Myeloma Patients - IMS 2024
Posters
11/08/2024
Urine Bence Jones proteins as a novel source for De Novo light chain sequencing - IMS 2024
Events
11/08/2024
American Society of Hematology - ASH 2024
Articles
08/28/2024
Advances in minimal residual disease monitoring in multiple myeloma - Clinical Laboratory Sciences 2023
Posters
08/28/2024
Single MS assay targeting m-protein, therapeutic antibodies, polyclonal immunoglobulins provides unique insight into therapy response kinetics in patients with MM - EMN 2024
Posters
08/26/2024
Next Generation Monitoring: M-inSight® Clinical Application In Multiple Myeloma - ADLM 2024
Events
08/22/2024
International Myeloma Society - IMS 2024
Articles
08/22/2024
An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and MRD monitoring in MM patients - CCLM 2024
Articles
08/22/2024
M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator - CCLM 2024
Events
03/19/2024
European Myeloma Network Meeting - EMN 2024
Posters
12/20/2023
Monitoring of Systemic Light-Chain Amyloidosis patients using Mass Spectrometry (M-inSight) in serum - ASH 2023
Posters
12/20/2023
Multiple Myeloma MRD tracking in blood using ultra sensitive Mass Spectrometry (M-inSight) - ASH 2023
Posters
10/05/2023
Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients - IMS 2023
Articles
09/28/2023
Sebia launches M-inSight®, a test for monitoring multiple myeloma patients
Articles
08/28/2023
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma - Cancers 2021